SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Elisabet Matas, Laura Bau, María Martínez-Iniesta, Lucía Romero-Pinel, Maria Alba Mañé-Martínez, Sergio Martínez-Yélamos, Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients, Journal of Neurology, 2016, 263, 4, 722

    CrossRef

  2. 2
    T. Spelman, T. Kalincik, V. Jokubaitis, A. Zhang, F. Pellegrini, H. Wiendl, S. Belachew, R. Hyde, F. Verheul, A. Lugaresi, E. Havrdova, D. Horakova, P. Grammond, P. Duquette, A. Prat, G. Iuliano, M. Terzi, G. Izquierdo, R. M. M. Hupperts, C. Boz, E. Pucci, G. Giuliani, P. Sola, D. L. A. Spitaleri, J. Lechner-Scott, R. Bergamaschi, F. Grand'Maison, F. Granella, L. Kappos, M. Trojano, H. Butzkueven, Comparative efficacy of first-line natalizumab vs IFN-  or glatiramer acetate in relapsing MS, Neurology: Clinical Practice, 2016, 6, 2, 102

    CrossRef

  3. 3
    Letizia Leocani, Maria A. Rocca, Giancarlo Comi, MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis, Current Opinion in Neurology, 2016, 29, 3, 243

    CrossRef

  4. 4
    Federica Esposito, Melissa Sorosina, Linda Ottoboni, Elaine T. Lim, Joseph M. Replogle, Towfique Raj, Paola Brambilla, Giuseppe Liberatore, Clara Guaschino, Marzia Romeo, Thomas Pertel, James M. Stankiewicz, Vittorio Martinelli, Mariaemma Rodegher, Howard L. Weiner, David Brassat, Christophe Benoist, Nikolaos A. Patsopoulos, Giancarlo Comi, Wassim Elyaman, Filippo Martinelli Boneschi, Philip L. De Jager, A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity, Annals of Neurology, 2015, 78, 1
  5. 5
    Mike P. Wattjes, Àlex Rovira, David Miller, Tarek A. Yousry, Maria P. Sormani, Nicola de Stefano, Mar Tintoré, Cristina Auger, Carmen Tur, Massimo Filippi, Maria A. Rocca, Franz Fazekas, Ludwig Kappos, Chris Polman, Frederik Barkhof, Xavier Montalban, Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients, Nature Reviews Neurology, 2015, 11, 10, 597

    CrossRef

  6. 6
    M. Romeo, V. Martinelli, M. Rodegher, E. Perego, S. Maida, M. P. Sormani, G. Comi, Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients, European Journal of Neurology, 2015, 22, 6
  7. 7
    C.R.N. Polachini, R.M. Spanevello, E.A. Casali, D. Zanini, L.B. Pereira, C.C. Martins, J. Baldissareli, A.M. Cardoso, M.F. Duarte, P. da Costa, A.L.C. Prado, M.R.C. Schetinger, V.M. Morsch, Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis, Neuroscience, 2014, 266, 266

    CrossRef

  8. 8
    A. H. V. Schapira, Recent advances in neurology 2013–2014, European Journal of Neurology, 2014, 21, 12
  9. 9
    Maria Pia Sormani, Nicola De Stefano, Defining and scoring response to IFN-β in multiple sclerosis, Nature Reviews Neurology, 2013, 9, 9, 504

    CrossRef